ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,887 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentZugSarepta International Holdings GmbH
Sarepta International Holdings GmbH Logo
Verified· 2 sourcesTrust Score
Summary

About the company

The core activity of Sarepta Therapeutics is the development and manufacturing of gene therapies for the treatment of rare diseases, particularly muscular dystrophies such as Duchenne muscular dystrophy, limb-girdle muscular dystrophy (LGMD), and Charcot-Marie-Tooth disease. The company focuses on researching and developing precision gene medicine and aims to increase efficiency in drug development and shorten the time from laboratory to patient.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Sarepta International Holdings GmbH

✓ Offered8
Precision genetic medicine for rare diseases
Precision genetic medicine for rare diseases, developed through Gene Therapy, RNA technologies and Gene Editing; focus on neuromuscular and other rare genetic disorders.
Gene therapy development
Gene therapy development to supplement missing or faulty genes; includes the Gene Therapy Engine and the development of therapies for rare genetic disorders.
RNA technologies
RNA technologies using an Exon-Skipping approach for the treatment of genetic disorders; part of the Precision-Genetic-Medicine platform and focused on rare diseases.
Gene editing
Gene editing to remove or cut out mutated exons, including with CRISPR/Cas9; part of the development work for rare genetic diseases.
Clinical studies
Clinical studies for investigational therapies in various stages of development; carefully designed and conducted to develop treatments for rare diseases.
Pipeline development
Development pipeline with more than 40 investigational therapies across different stages; focus on genetic disorders, including Duchenne, LGMD and Charcot-Marie-Tooth.
Grants & Giving
Grants, donations, medical education support and sponsorships for advocacy groups, non-profits, academic institutions and medical professional organisations in the field of rare diseases.
Research collaborations
Strategic partnerships and investigator-initiated studies to advance research in rare genetic disorders and to support development programmes.
Trust & reputation

ranQ Trust Score of Sarepta International Holdings GmbH: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 54% · As of October 2026

Without public customer reviews the score stays capped.

Sarepta International Holdings GmbH has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Sarepta International Holdings GmbH scores 75.7 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.83.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
Sarepta International Holdings GmbH scores 83.3 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).83.322%
Sarepta International Holdings GmbH scores 40.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.40.04%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

Sarepta International Holdings GmbH reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once Sarepta International Holdings GmbH has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Sarepta International Holdings GmbH in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Sarepta International Holdings GmbH by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Sarepta International Holdings GmbH to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Baarerstrasse 14
6300 Zug

At a glance

Legal form
Limited Liability Company
UID
CHE-319.605.632
Founded
2017 · 9 years
Last commercial register change
October 17, 2023
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.88.06%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    SH
    Swissi Holding AG
    Zug
    CT
    Corcept Therapeutics Switzerland GmbH
    Zug
    IS
    Insmed Switzerland GmbH
    Zug
    PR
    Premier Research Group SA
    Zug
    OT
    Orchard Therapeutics (Switzerland) GmbH
    Zug
    CT
    CRISPR Therapeutics AG
    Zug
    GS
    G&L Scientific (Schweiz) GmbH
    Zug
    RP
    Rhythm Pharmaceuticals Switzerland GmbH
    Zug